Panacea Biotec Intrinsic Value
Panacea Biotec (PANACEABIO) median intrinsic value is ₹1060.75 from 2 valuation models (range ₹849–₹1061), vs current price ₹424.30 — +150.0% upside (Trading Below Calculated Value), margin of safety 60.0%. For current market price and key ratios, visit Panacea Biotec share price screener.
PANACEABIO Valuation Methods Summary — DCF, Graham Number & P/E
Panacea Biotec intrinsic value across 2 models vs current price ₹424.30 — upside/downside and value range per method. Browse Panacea Biotec annual reports for revenue, profit, balance sheet and cash flow data.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹1060.75 | ₹954.68 - ₹1166.83 | +150.0% | Book Value/Share: ₹1385.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹848.60 | ₹763.74 - ₹933.46 | +100.0% | Revenue/Share: ₹1000.00, P/S: 2.0x |
PANACEABIO Intrinsic Value vs Market Price — All Valuation Models
Panacea Biotec fair value range ₹849–₹1061 vs current market price ₹424.30 across 2 valuation models. Also explore PANACEABIO share price charts to track price trends across different timeframes.
PANACEABIO Intrinsic Value Analysis — Undervalued or Overvalued?
Panacea Biotec median intrinsic value ₹1060.75, current price ₹424.30 — Trading Below Calculated Value by 150.0%, margin of safety 60.0%.
What is the intrinsic value of PANACEABIO?
Based on our comprehensive analysis using 2 different valuation methods, the estimated intrinsic value of Panacea Biotec (PANACEABIO) is ₹1060.75 (median value). With the current market price of ₹424.30, this represents a +150.0% variance from our estimated fair value.
The valuation range spans from ₹848.60 to ₹1060.75, indicating ₹848.60 - ₹1060.75.
Is PANACEABIO undervalued or overvalued?
Based on our multi-method analysis, Panacea Biotec (PANACEABIO) appears to be trading below calculated value by approximately 150.0%.
PANACEABIO Financial Health — Key Ratios vs Industry Benchmarks
Panacea Biotec financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 5.92 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | -6.7% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | -13.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.47x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
PANACEABIO Cash Flow Quality — Operating & Free Cash Flow
Panacea Biotec operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-27 Cr | ₹-27 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹-423 Cr | ₹-423 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹-108 Cr | ₹-108 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹107 Cr | ₹83 Cr | Positive Free Cash Flow | 8/10 |